Correction to: COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study

Węcławek-Tompol, Jadwiga; Zakrzewska, Zuzanna; Gryniewicz–Kwiatkowska, Olga; Pierlejewski, Filip; Bień, Ewa; Zaucha‐Prażmo, Agnieszka; Zając‐Spychała, Olga; Szmydki‐Baran, Anna; Mizia‐Malarz, Agnieszka; Bal, Wioletta; Sawicka-Żukowska, Małgorzata; Kruk, Agnieszka; Ociepa, Tomasz; Raciborska, Anna; Książek, Agnieszka; Szczepański, Tomasz; Peregud-Pogorzelski, Jarosław; Krawczuk‐Rybak, Maryna; Chaber, Radosław; Matysiak, Michał; Wachowiak, Jacek; Irga‐Jaworska, Ninela; Młynarski, Wojciech; Dembowska‐Bagińska, Bożenna; Balwierz, Walentyna; Matkowska-Kocjan, Agnieszka; Kazanowska, Bernarda; Styczyński, Jan; Ussowicz, Marek

doi:10.1186/s13045-022-01279-3

Cited by 4 publications

(6 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The withdrawal or delay of cancer treatment, after COVID-19 infection, has been the practice of many pediatric cancer centers during the pandemic. 10,[13][14][15]18,26,27 Our results add to emerging evidence that the continuance of cancer-directed therapy is safe, particularly for those who are asymptomatic or with mild symptoms. 16,20,33,42,43 The long-term impact of treatment delays incurred due to the COVID-19 pandemic is not yet known.…”

Section: Discussionmentioning

confidence: 55%

“…Also, population vaccination rates increased, substantially limiting severe infections 28,32–34 . These developments evolved over time and could have impacted pediatric oncology patients 6,8–15,27,28,32–34 . As such, we might expect outcomes from studies considering COVID-19 infection early in the pandemic to be comparable and outcomes from later studies, while differing from early data, to be comparable with those from the same time period.…”

Section: Discussionmentioning

confidence: 99%

“…28,[32][33][34] These developments evolved over time and could have impacted pediatric oncology patients. 6,[8][9][10][11][12][13][14][15]27,28,[32][33][34] As such, we might expect outcomes from studies considering COVID-19 infection early in the pandemic to be comparable and outcomes from later studies, while differing from early data, to be comparable with those from the same time period. Support for this outcome variability explanation is weakened, as data emergent from similar time periods has not been consistent.…”

Section: Discussionmentioning

confidence: 99%

“…7,[9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] COVID-19 infection has also resulted in the delay or withdrawal of cancer-directed therapy. 7,[13][14][15][16][17]26,27 To date, data for Canadian childhood cancer patients with COVID-19 have not been reported apart from 4 pediatric centers in Quebec. 15 The primary objectives of this study were to describe patient characteristics at the time of COVID-19 infection and outcomes of infection; including interruptions to cancer therapy, hospitalization, and associated mortality, in children with cancer treated at 12 Canadian pediatric oncology centers between January 2020 and December 2021.…”

mentioning

confidence: 99%

“…Significant heterogeneity in COVID-19 outcomes for children with cancer has been observed; hospitalization rates, an imperfect surrogate marker of moderate-severe infection, range from 5% to 68.1%, intensive care unit (ICU) admissions from 0% to 25%, and mortality from 0% to 4.3% 7,9–26 . COVID-19 infection has also resulted in the delay or withdrawal of cancer-directed therapy 7,13–17,26,27 …”

mentioning

confidence: 99%

See 4 more Smart Citations

Outcomes of Coronavirus Disease 2019 Infection in Children and Adolescents With Cancer in Canada: Population-based Study and Systematic Review

Mark

Gibson

Lafay‐Cousin

et al. 2023

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Published outcomes for children with cancer with coronavirus disease 2019 (COVID-19) have varied. Outcome data for pediatric oncology patients in Canada, outside of Quebec, have not been reported. This retrospective study captured patient, disease, and COVID-19-related infectious episode characteristics and outcome data for children, 0 to 18 years, diagnosed with a first COVID-19 infection between January 2020 to December 2021 at 12 Canadian pediatric oncology centers. A systematic review of pediatric oncology COVID-19 cases in high-income countries was also undertaken. Eighty-six children were eligible for study inclusion. Thirty-six (41.9%) were hospitalized within 4 weeks of COVID-19; only 10 (11.6%) had hospitalization attributed to the virus, with 8 being for febrile neutropenia. Two patients required intensive care unit admission within 30 days of COVID-19 infection, neither for COVID-19 management. There were no deaths attributed to the virus. Of those scheduled to receive cancer-directed therapy, within 2 weeks of COVID-19, 20 (29.4%) experienced treatment delays. Sixteen studies were included in the systematic review with highly variable outcomes identified. Our findings compared favorably with other high-income country's pediatric oncology studies. No serious outcomes, intensive care unit admissions, or deaths, in our cohort, were directly attributable to COVID-19. These findings support the minimization of chemotherapy interruption after COVID-19 infection.

show abstract

Section: Discussionmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Outcomes of Coronavirus Disease 2019 Infection in Children and Adolescents With Cancer in Canada: Population-based Study and Systematic Review

Mark

Gibson

Lafay‐Cousin

et al. 2023

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

Developing Allosteric Inhibitors of SARS‐CoV‐2 RNA‐Dependent RNA Polymerase

Chayka,

Danda,

Dostálková

et al. 2024

ChemMedChem

View full text Add to dashboard Cite

The use of Fpocket and virtual screening techniques enabled us to identify potential allosteric druggable pockets within the SARS‐CoV‐2 RNA‐dependent RNA polymerase (RdRp). Of the compounds screened, compound 1 was identified as a promising inhibitor, lowering a SARS‐CoV‐2 RdRp activity to 57% in an enzymatic assay at 10 µM concentration. The structure of compound 1 was subsequently optimized in order to preserve or enhance inhibitory activity. This involved the substitution of problematic ester and aromatic nitro groups with more inert functionalities. The N,N’‐diphenylurea scaffold with two NH groups was identified as essential for the compound's activity but also exhibited high toxicity in Calu‐3 cells. To address this issue, a scaffold hopping approach was employed to replace the urea core with potentially less toxic urea isosteres. This approach yielded several structural analogues with notable activity, specifically 2,2’‐bisimidazol (in compound 55 with residual activity RA = 42%) and (1H‐imidazol‐2‐yl)urea (in compounds 59 and 60, with RA = 50 and 28%, respectively). Despite these advances, toxicity remained a major concern. These compounds represent a promising starting point for further structure‐activity relationship studies of allosteric inhibitors of SARS‐CoV‐2 RdRp, with the goal of reducing their cytotoxicity and improving aqueous solubility.

show abstract